US PTAB Patent Cases
8,574 decisions indexed
Page 144 of 286 · 8,574 total
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has filed a post‑grant review petition seeking cancellation of all 31 claims of Solmetex’s dental mouthpiece patent, alleging obviousness, lack of written description, and indefiniteness. The petition leans on three earlier patents and expert testimony to argue the claims are unpatentable.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung and co‑petitioners have filed a PGR seeking to invalidate claim 7 of Omni MedSci’s 12,193,790 patent, arguing obviousness over Lisogurski and Carlson and invoking collateral estoppel from earlier IPRs.
North Sails Group, LLC v.Team New Zealand Limited et al.
North Sails has filed a post‑grant review petition challenging Team New Zealand’s high‑performance sail patent (US 12,110,089). The petitioner alleges anticipation, obviousness, indefiniteness, lack of enablement and insufficient written description, citing a range of prior‑art references and prior sales. The PTAB has yet to rule on the petition.
TankLogix, LLC v.SitePro, Inc.
TankLogix has filed a post‑grant review petition seeking cancellation of all 31 claims of SitePro’s ‘184 patent covering remote control of fluid‑handling equipment, arguing abstract‑idea ineligibility, obviousness over four prior references, and lack of written‑description support.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a Post‑Grant Review petition challenging Halozyme’s U.S. Patent 12,037,618 covering engineered PH20 hyaluronidase proteins. The petition argues the claims lack written description, are not enabled, and are obvious over prior patents and publications.
Intas Pharmaceuticals, Ltd. et al. v.Atossa Therapeutics, Inc.
Intas Pharmaceuticals petitions the PTAB to invalidate all 44 claims of Atossa’s 391 patent covering 90% (Z)-endoxifen compositions, asserting anticipation, obviousness, and lack of written description.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck challenges Halozyme’s broad PH20 hyaluronidase patent, asserting lack of written description, enablement, and obviousness. The petition seeks to invalidate all 40 claims.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a Post‑Grant Review petition challenging Halozyme’s U.S. Patent 12,104,185 covering modified PH20 hyaluronidase proteins. The petition argues the claims are overly broad, lack written description and enablement, and are obvious in view of prior art. The case is pending institution.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a Post‑Grant Review petition challenging Halozyme’s U.S. Patent No. 12,054,758 covering engineered PH20 hyaluronidase proteins, arguing lack of written description, enablement, and obviousness.
Alliance Laundry Systems, LLC v.PayRange LLC.
Alliance Laundry Systems petitions the PTAB to review PayRange’s 2024 patent covering mobile‑device‑driven vending‑machine payments. The petition asserts anticipation, obviousness, and § 101 ineligibility for all 20 claims, citing Low, Arora, Freeny and Casey as prior art.
Neurocrine Biosciences, Inc. v.Spruce Biosciences, Inc.
Neurocrine Biosciences petitions the PTAB to invalidate Spruce Biosciences’ 12,115,166 patent covering a broad genus of CRF1 receptor antagonists for CAH, arguing lack of written description and enablement.
Alliance Laundry Systems, LLC v.PayRange LLC.
Alliance Laundry Systems petitions the PTAB to invalidate PayRange’s 2024 mobile‑payment patent covering vending‑machine transactions, arguing obviousness and patent‑ineligibility. The petition also rebuts any discretionary denial.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a PGR petition challenging Halozyme’s U.S. Patent 12,060,590 covering thousands of engineered PH20 hyaluronidase variants, asserting lack of written description, enablement, and obviousness.
Multi-Color Corporation v.Brook & Whittle Ltd.
Multi-Color Corp. has filed a post‑grant review petition seeking cancellation of Brook & Whittle’s recyclable shrink‑label patent, alleging anticipation, obviousness, and indefiniteness.
Tesla, Inc. v.Perceptive Automata LLC
Tesla has filed an IPR petition seeking cancellation of all 23 claims of Perceptive Automata’s autonomous‑vehicle patent, asserting that the claims are obvious over prior‑art machine‑learning and sensor‑fusion publications such as Djuric, Zhu, Cox, and Ross.
ITM Isotope Technologies Munich SE v.The Johns Hopkins University et al.
ITM Isotope Technologies Munich SE petitions the PTAB to invalidate claims of Johns Hopkins' ’201 patent covering low‑molecular‑weight FAP‑α imaging agents, arguing obviousness, lack of enablement, insufficient written description, and indefiniteness.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a Post‑Grant Review petition challenging Halozyme’s U.S. Patent 12,123,035 covering PH20 hyaluronidase mutants. The petition asserts lack of written description, lack of enablement, and obviousness of the claims. The Board has yet to decide whether to institute the trial.
Intelligent Wellhead Systems, Inc. et al. v.Downing Wellhead Equipment, LLC et al.
Intelligent Wellhead Systems has filed a PGR petition seeking cancellation of all 78 claims of Downing's hydraulic fracturing patent, arguing the claims are abstract, lack written description, contain new matter, and are obvious over multiple prior‑art references.
Senko Advanced Components, Inc. v.US Conec Ltd.
Senko Advanced Components petitions the PTAB to invalidate US Conec's 11,808,994 patent covering small form‑factor fiber‑optic connectors, alleging indefiniteness, lack of written description, anticipation and obviousness over numerous prior‑art references.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a post‑grant review petition challenging Halozyme’s U.S. Pat. 11,952,600, arguing that the claims lack written description, are not enabled, and are obvious over prior art.
UATP IP, LLC et al. v.Slick Slide LLC
UATP IP petitions PTAB to invalidate Slick Slide's low‑friction slide patent, asserting obviousness over Phillips, Fallgatter, and a nylon‑mesh product, plus lack of enablement and indefiniteness. The petition seeks institution and a finding that the challenged claims are unpatentable.
Ecto World, LLC d/b/a Demand Vape et al. v.RAI Strategic Holdings, Inc. et al.
Ecto World petitions PTAB to invalidate RAI Strategic's 2024 electronic‑cigarette patent, arguing lack of written description and obviousness over Takeuchi, Kim, Pienemann and Susa. The petition seeks institution and opposes discretionary denial.
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody has filed a post‑grant review petition seeking cancellation of 14 claims of Hyperice’s percussive‑massager patent, alleging lack of written description, indefiniteness, and obviousness over multiple prior‑art references.
Tesla, Inc. v.Perceptive Automata LLC
Tesla has filed an IPR petition challenging Perceptive Automata’s AI‑driven image‑analysis patent (U.S. 11,753,046). The petition asserts obviousness over four prior‑art references and argues that many claim elements are non‑patentable printed matter.
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
Samsung has filed a PGR petition seeking cancellation of all 16 claims of Oura’s wearable ring patent, arguing obviousness over three prior‑art references and urging the Board not to deny institution.
Godbersen-Smith Construction Company d/b/a GOMACO Corporation v.Guntert & Zimmerman Const. Div., Inc.
GOMACO has filed a post‑grant review petition seeking cancellation of claims 1‑7 of its ‘723 slipform paver patent. The petition alleges obviousness over the CIII manual, Rio and Files patents, and a lack of written description for a transducer placement. The Board has yet to decide whether to institute the proceeding.
Voltage, LLC et al. v.Shoals Technologies Group, LLC
Voltage, LLC has petitioned the PTAB to invalidate Shoals Technologies' U.S. Patent 11,689,153 covering solar lead assemblies. The petition alleges obviousness over multiple prior‑art references and indefiniteness under § 112. The Board must decide whether to institute the review.
LUMI LEGEND CORPORATION v.Manehu Product Alliance, LLC
Lumi Legend has filed a PGR petition seeking cancellation of claims 33‑36 of U.S. Patent 11,781,703, alleging lack of written description, indefiniteness, anticipation, and obviousness. The petition relies on prior art such as Clary, Juan, Pankros, Tsuji, and Xu. It also argues the patent is eligible for PGR and urges the Board not to deny institution.
Toyota Motor Corporation et al. v.BUNKER HILL TECHNOLOGIES, LLC
Toyota has filed an IPR petition seeking cancellation of all 17 claims of Bunker Hill’s ’508 hybrid‑drive patent, alleging anticipation and obviousness over multiple prior‑art references. The petition relies on a technical expert declaration and argues no secondary considerations exist.
Nexus Pharmaceuticals LLC v.Exela Pharma Sciences, LLC
Nexus Pharmaceuticals has filed a PGR petition challenging all 30 claims of Exela Pharma Sciences' L‑cysteine parenteral nutrition patent, asserting lack of enablement, insufficient written description, and, alternatively, obviousness over the Sandoz label.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.